Despite a flood of “artificial” ingredients in the food, supplement and cosmetic industries, conscious consumers continue to insist upon natural herbal extracts in the products they put both into and onto their bodies. In response, Sami Labs (Bangalore, India), manufacturer and marketer of products for the pharmaceutical and food industries and parent company of phytonutrient supplier and research firm Sabinsa, inaugurated its second continuous extraction plant on October 5, 2017, largely to satisfy demand for its Curcumin C3 Complex.
Sami has dedicated the new facility exclusively to curcumin extraction and intends for the plant to increase the company’s production capacity of natural, bioavailable Curcumin C3 Complex fourfold—taking the previous production of 6 tons to 25 tons. Both continuous extraction units are situated across 5 acres in Dobaspet, Bangalore, India.
The production increase that this new facility allows comes just in time, as preference for natural curcumin, coupled with continuing research supporting its benefits, has yielded a curcumin market set to exceed $100 million by 2023, representing a CAGR of 12.6 percent from 2017 to 2023, the company states in a press release (citing Frost & Sullivan research). And though dietary supplements, pharmaceuticals and cosmetics still drive curcumin’s growth, nutraceuticals are responsible for more than half of curcumin demand share by volume and revenue, and continue to grow faster than the other segments, the press statement says.
“Because of turmeric’s historic place in India’s traditional medical system Ayurveda, India dominates world turmeric production, with 80% taking place here,” Dr. Muhammed Majeed, founder and chairman, Sami-Sabinsa Group, says in the press statement. “With our Curcumin C3 Complex the world leader in curcumin ingredients, expanding extraction capacity to ensure that we can continue to meet demand was the logical next step.”